Preoperative Immunotherapy Combined with Chemotherapy for Triple-Negative Breast Cancer: Perspective on the KEYNOTE-522 Study

Stephanie Downs-Canner¹, Elizabeth A Mittendorf^{2

3

4}

Affiliations

¹ Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. emittendorf@bwh.harvard.edu.
³ Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. emittendorf@bwh.harvard.edu.
⁴ Harvard Medical School, Boston, MA, USA. emittendorf@bwh.harvard.edu.

Editorial

Stephanie Downs-Canner et al. Ann Surg Oncol. 2023 Jun.

. 2023 Jun;30(6):3166-3169.

doi: 10.1245/s10434-023-13267-z. Epub 2023 Mar 10.

Stephanie Downs-Canner¹, Elizabeth A Mittendorf^{2

3

4}

¹ Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. emittendorf@bwh.harvard.edu.
³ Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. emittendorf@bwh.harvard.edu.
⁴ Harvard Medical School, Boston, MA, USA. emittendorf@bwh.harvard.edu.

Erratum in

Correction: Preoperative Immunotherapy Combined with Chemotherapy for Triple-Negative Breast Cancer: Perspective on the KEYNOTE-522 Study.
Downs-Canner S, Mittendorf EA. Downs-Canner S, et al. Ann Surg Oncol. 2023 Jun;30(6):3286. doi: 10.1245/s10434-023-13448-w. Ann Surg Oncol. 2023. PMID: 37014560 No abstract available.

No abstract available

1. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502. - DOI - PubMed
1. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–34. - DOI - PubMed
1. Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817–28. - DOI - PubMed
1. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–21. - DOI - PubMed
1. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–21. - DOI - PubMed